Core Insights - Rongchang Biotech is expected to achieve multiple clinical advancements, product approvals, and partnership milestones by 2026 [1] Stock Performance - The overseas Phase III clinical trial for Taitasip in treating myasthenia gravis continues to enroll participants, with completion anticipated in the first half of 2026 [2] - Taitasip has received FDA fast track designation for primary Sjögren's syndrome, with a global Phase III trial likely to commence [2] - The global Phase II registration trial for Vidisizumab in second-line urothelial carcinoma has been completed, and the accelerated enrollment for the Phase III trial in first-line urothelial carcinoma is ongoing, with Pfizer expected to submit an overseas marketing application in the first half of 2026 [2] Project Progress - New indications for Vidisizumab and the ophthalmic drug RC28 are expected to receive approval in the second to third quarter of 2026 [3] - The indication for Taitasip in IgA nephropathy is anticipated to be approved in the fourth quarter [3] - Core product RC148 (PD-1/VEGF dual antibody) has three Phase III clinical trials approved, with overseas development plans being noteworthy [3] Related Transactions - An upfront payment of $650 million from the licensing agreement with AbbVie for RC148 will be reflected in the 2026 performance, with the total transaction amount reaching $5.6 billion [4] - Subsequent milestone payments from collaborations with Vor Bio and Santen Pharmaceutical may also progress [4] Product Development Progress - RC278 (targeting CDCP1 ADC) has entered Phase I/II clinical trials [5] - RC288 (bispecific ADC) is planned to initiate clinical trials in early 2026 [5]

Group 1 - The company announced plans to acquire a controlling stake in Jiangyin Sulong Thermal Power Co., Ltd. through a combination of issuing shares and cash payment, along with raising matching funds [1][3] - This transaction is expected to constitute a major asset restructuring and related party transaction, but will not result in a restructuring listing. The company's stock will be suspended from trading starting February 13 [3] - The company has signed a "Share Acquisition Intent Agreement" with Jiangyin Electric Power Investment Co., Ltd., the controlling shareholder of Sulong Thermal Power, with the final price to be determined based on an evaluation report from a qualified appraisal agency [3] Group 2 - Jiangyin Sulong Thermal Power has a registered capital of 2.4 billion yuan, and its business scope includes power generation, transmission, and supply, as well as port operations and special equipment design [3] - The largest shareholder of the company is Jiangyin Chengbang Enterprise Management Development Center (Limited Partnership), holding a 29.02% stake, with Jiangyin Xinguolian Group Co., Ltd. owning 89.88% of Chengbang's capital [4]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002653 证券简称：海思科 公告编号：2026-017 海思科医药集团股份有限公司 第五届董事会第三十六次会议 决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 表决结果：4票同意、0票弃权、0票反对 关联董事王俊民先生回避表决，公司独立董事对该事项进行了事前审议。 公司拟与海利克斯（成都）医药科技有限公司（以下简称"海利克斯"）共同投资9,700万元人民币设立 子公司海思生物科技有限责任公司（拟用名称，以工商登记为准，以下简称"海思生物"）,其中公司投 资8,700万元人民币，占海思生物股权比例89.69%，海利克斯投资1,000万元人民币，占海思生物股权比 例10.31%； 公司拟与海利克斯共同投资4,850万元人民币设立子公司海思新元医药科技有限责任公司（拟用名称， 以工商登记为准，以下简称"海思新元"）,其中公司投资4,350万元人民币，占海思新元股权比例 89.69%，海利克斯投资500万元人民币，占海思新元股权比例10.31%。 详见同日刊登在巨潮资讯网等公司指定信息披露媒体的 ...

Core Viewpoint - Shenzhen Zhongke Lanyun Technology Co., Ltd. is engaging in a related party investment with its controlling shareholder's family members, which constitutes a related party transaction but does not qualify as a major asset restructuring [2][3][5]. Group 1: Related Party Transaction Overview - The company, in collaboration with Zhongxin Juyuan Private Equity Fund Management (Shenzhen) Co., Ltd., established Jiaxing Juyuan Langrui Equity Investment Partnership (Limited Partnership) with a total subscribed capital of RMB 24.381 million, where the company contributed RMB 8 million, accounting for 32.81% of the total [4][20]. - To meet future investment needs, the partnership plans to increase its capital from RMB 24.381 million to RMB 44.276 million, with the controlling shareholder's family members investing a total of RMB 1 million [4][21]. - The transaction has been approved by the company's board of directors and does not require shareholder approval as it falls within the board's authority [5][16]. Group 2: Related Party Basic Information - Cai Meng, the spouse of the company's controlling shareholder and chairman, and Huang Hening, their daughter, are identified as related natural persons under the Shanghai Stock Exchange rules [6]. - There are no other relationships between these individuals and the company regarding property, business, assets, debts, or personnel [6]. Group 3: Investment Partnership Details - The partnership is named Jiaxing Juyuan Langrui Equity Investment Partnership (Limited Partnership) and is registered in Jiaxing, Zhejiang Province [8]. - The partnership's business scope includes equity investment and private equity activities, pending registration with the China Securities Investment Fund Industry Association [8]. Group 4: Purpose and Impact of the Related Party Transaction - The company's participation in establishing Juyuan Langrui aligns with its strategic development needs, helping to broaden investment channels and leverage professional management capabilities [15]. - The capital increase aims to expand the fund's investment scale and enhance financial strength to seize quality investment opportunities [15].

Group 1 - The company held its 13th meeting of the 4th Board of Directors on February 12, 2026, to discuss and approve a proposal regarding the provision of equity pledge guarantees and related transactions [2][3] - The proposal was approved with 7 votes in favor, 0 against, and 0 abstentions, with 2 members abstaining due to conflicts of interest [2][3] - The company’s wholly-owned subsidiary, Shenzhen Yihong Investment Co., Ltd., plans to provide a pledge guarantee for a fixed asset loan of 375 million yuan to its associate company, Shenzhen Yifeng Zhixin Packaging Technology Co., Ltd. [2][31] Group 2 - The proposal will be submitted to the shareholders' meeting for further approval [4][9] - The company has received a request from a major shareholder to add the proposal to the agenda of the upcoming shareholders' meeting [9][10] - The shareholders' meeting is scheduled for February 25, 2026, and will combine on-site voting with online voting [11][12] Group 3 - The company’s total external guarantee amount is 203.5 million yuan, with the new guarantee increasing the total to 138.91 million yuan, which represents 67.40% of the company's latest audited net assets [46] - The company has no overdue guarantees or guarantees involved in litigation [46]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ●交易简要内容 江苏索普化工股份有限公司（以下简称"公司"）拟向公司控股股东江苏索普（集团）有限公司（以下简 称"索普集团"）购买部分土地使用权及建筑物，交易标的资产为权证编号分别为镇国用(2007)第5789 号、镇国用(2002)字第1123939号、苏(2022)镇江市不动产权第0090466号的权属证书所记载的土地使用 权及地上建筑物。标的资产经评估价值为4,864.19万元人民币（含增值税），拟交易价格为4,864.19万元 人民币（含增值税）。 ●交易实施尚需履行的审批及其他相关程序 因索普集团系公司控股股东，本次交易构成关联交易，本次交易已经公司独立董事专门会议2026年第一 次会议，第十届董事会第十四次会议审议通过。公司董事会授权公司经理层办理本事项包括签订协议在 内的相关具体事宜。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600746证券简称：江苏索普公告编号：临2026-002 江苏索普化工股份有限公司关于购买控股股东资产暨 ...

Group 1 - The company held its 12th meeting of the 9th Board of Directors on February 12, 2026, with all 9 directors present, complying with relevant laws and regulations [2] - The Board approved the proposal to use idle self-owned funds to purchase cash management products, with an annual purchase limit of up to RMB 1.5 billion, allowing for rolling use within this limit [3][10] - The cash management products will include low-risk financial products such as structured deposits, notice deposits, large certificates of deposit, and time deposits [10][15] Group 2 - The company approved the expected daily related transactions for 2026, with a total estimated amount of RMB 241 million, involving 9 related parties [30] - The related transactions include sales of products worth RMB 63.6 million, provision of services worth RMB 19.2 million, and purchase of raw materials worth RMB 95 million [30][41] - The Board's independent directors confirmed that the expected related transactions are beneficial for the company's normal business operations and do not harm the interests of non-related shareholders [5][42]

上市公司中南文化（SZ002445，股价2.78元，市值66.07亿元）打算跨界。 2月13日（周五）开市起，中南文化将正式停牌。根据12日晚间披露的公告，中南文化拟通过发行股份 及支付现金的方式，购买江阴苏龙热电有限公司（以下简称苏龙热电）的控股权——该公司背靠江阴国 资，手握56亿元投资的扩建项目。 《每日经济新闻》记者注意到，中南文化曾高调布局文化传媒板块，而如今相关营收占比已跌至1%附 近。 当时，公司表示会严格按照相关要求披露信息，若达到披露标准，将及时履行信息披露义务。仅仅三个 月后，这一纸停牌公告，算是给了投资者一个迟到但确定的答案。 构成关联交易 在此次停牌公告发布之前，市场对于中南文化的转型已有诸多猜测，但标的资产的体量仍超预期。 根据中南文化发布的《关于筹划重大资产重组事项的停牌公告》，公司正在筹划购买苏龙热电的控股 权。公告显示，初步确定的交易对方为江阴电力投资有限公司。而天眼查的穿透信息显示，该公司的法 定代表人正是中南文化现任董事长薛健。 苏龙热电成色几何？公开资料显示，苏龙热电成立于1993年，是由江阴市新国联集团、中国华电集团等 单位共同投资的火电企业。作为江阴市主要的电源点和热 ...

公司股东长峡金石及其一致行动人在2025年12月8日至2026年1月22日期间通过集中竞价方式合计减持 1275.78万股，持股比例从6.00%降至5.00%以下。根据公告，该股东未来十二个月内可能继续减持。 业绩经营情况 经济观察网宝钢包装（601968）近期在关联交易、股东减持及财务业绩方面有重要动态。公司临时股东 会审议通过了2026年度预计日常关联交易议案，总额11.50亿元；股东长峡金石及其一致行动人近期减 持股份，持股比例降至5%以下；公司前三季度营收与净利润均实现同比增长。 关联交易情况 宝钢包装于2026年2月9日召开了2026年第二次临时股东会，审议了《关于宝钢包装2025年度关联交易执 行情况和2026年度预计日常关联交易的议案》。该议案预计2026年度日常关联交易总额为11.50亿元， 涉及向关联方采购原材料、销售产品等事项，交易遵循市场定价原则。 股东减持 截至2025年9月30日，宝钢包装2025年1-9月实现营业收入65.81亿元，同比增长6.83%；归母净利润1.76 亿元，同比增长11.97%。香港中央结算有限公司新进为第十大流通股东，持股830.93万股。 以上内容基于公开资 ...

Company - Alloy Investment (000633) held a temporary shareholders' meeting on December 29, 2025, to approve the proposal regarding the expected daily related transactions for the year 2026, which may impact its operational activities in 2026 [1][2] Industry - As a company in the non-ferrous metals and new materials sector, Alloy Investment may be influenced by overall industry dynamics, such as the recent increase in tungsten prices and other supply-demand factors, although no specific new announcements related to the company have been found [1][3]